KING OF PRUSSIA, PA — SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., has presented groundbreaking research at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. Their findings highlight the potential of novel orally bioavailable p300-selective degraders to treat challenging cancers, including prostate cancer and those with CBP protein deficiencies or mutations.
The p300 protein plays a critical role in driving tumor growth across a range of cancers. The research unveiled by SK Life Science Labs demonstrates that these targeted degraders shut down tumor cell proliferation with precision and potency. Administered orally once daily, p300-selective degraders showed rapid tumor reduction in preclinical models, particularly in cases of castrate-resistant prostate cancer and other hard-to-treat indications.
“What is extremely promising about our research is that we have shown that selective p300 degraders are highly effective in rapidly shutting down tumor growth in hard-to-treat cancers while also reducing toxicity due to their precise targeting,” stated Ryan Kruger, Ph.D., Chief Scientific Officer at SK Life Science Labs. “This study offers great hope for the development of safer drug therapies that could effectively treat some of the most challenging types of cancers for patients who currently have few good treatment options.”
A key advantage of the p300 degraders lies in their ability to selectively target the p300 protein while sparing the related protein CBP. Unlike existing treatments that merely suppress protein activity, these degraders fully eliminate p300, making them a promising therapeutic option for cancers that rely on this protein.
“There are two primary advantages of using a heterobifunctional degrader to target p300,” added Dr. Kruger. “First, using the power of ternary complex formation, we are for the first time able to generate molecules that can target p300 over CBP with exquisite selectivity. Second, p300 degraders eliminate this critical protein required for cancer cells instead of just suppressing its activity as other molecules in development do. This discovery underscores the potential for safer and more effective oncology therapies for some of the most difficult-to-treat cancers.”
SK Life Science Labs’ breakthrough represents significant progress in the fight against aggressive cancers and underscores their commitment to advancing innovative treatments that aim to improve patient care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.